Prime Medicine Inc

NASDAQ: PRME
$3.45
-$0.42 (-10.9%)
Closing Price on October 1, 2024

PRME Stock Chart and Intraday Price

PRME Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 21 ERIE ST., CAMBRIDGE, MA, US
Fiscal Year End December
Latest Quarter 9/30/2023
Market Cap 1,047.79M USD
Shares Outstanding 119,884,000
Prime Medicine Inc is a pioneering biotechnology firm based in Cambridge, Massachusetts, focused on advancing genetic therapies across a broad spectrum of diseases. Utilizing cutting-edge gene editing technology, Prime Medicine develops Prime Editors, innovative tools that enable precise DNA edits. These editors combine a Cas protein with a reverse transcriptase enzyme and a pegRNA for targeted action. The company is also exploring novel treatments for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome through a research partnership with Cimeio Therapeutics. Founded in 2019, Prime Medicine is at the forefront of genetic therapy innovation.

PRME Articles

Got $100? Consider Buying These 2 Penny Stocks in October (PRME, RLX)
You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part of investing is finding the right balance between risk and reward. As...
Joshua Rodriguez
Published:

Stock Offerings Prompt Big Insider Buying
Public offerings of stock tempted some insider buying, and one insider stepped up to support a struggling online delivery service provider.
Trey Thoelcke
Published: